Purdue student venture fund invests in Kylin Therapeutics

Purdue University’s Student-Managed Venture Fund is betting its bank on West Lafayette-based biotech startup Kylin Therapeutics

This month, MBA students in the Krannert Graduate School of Management invested $100,000 in Kylin, which represents 77 percent
of their fund’s total assets. Kylin, in the Purdue Research Park, is in the preclinical stage of commercializing a technology
to target and "turn off" diseasecausing genes.

Including the student’s investment, Kylin last month raised $2 million in a venture capital round led by West Lafayette-based
In-vivo Ventures and Durham, N.C.-based Golden Pine Ventures. The company plans to use the money to advance its cancer therapy
to the marketplace.

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our updated comment policy that will govern how comments are moderated.

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets in {{ count_down }} days.